Several studies and clinical trials in various cancer types have long been focusing on combining specific BRAFV600E inhibitors with other kinase or receptor growth factor inhibitors, like MEK, PI3K and EGFR [31-33, 44]. Here, MAP2K7 is linked to cancer.